Coca-Cola stock is downgraded to "Hold" with only 4% upside to $78.90. Here's what investors need to know about KO.
A twice-yearly injection may soon change how high blood pressure is treated. In a global trial, patients receiving the experimental drug zilebesiran alongside standard therapy saw greater blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results